The incidence of adverse reactions is classified according to the recommendations of the World Health Organization: very often (≥1 / 10); often (≥1 / 100, <1/10); infrequently (≥1 / 1000, <1/100); rarely (≥1 / 10000, <1/1000); very rarely (<1/10000), the frequency is unknown (the frequency of undesired reactions can not be estimated based on the available data).
Monotherapy
Infections and infestations: often - the flu.
Benign, malignant and unspecified neoplasms (including cysts and polyps): often - skin cancer.
Violations from the blood and lymphatic system: often - leukopenia.
Immune system disorders: often - allergies.
Metabolic and nutritional disorders: infrequent - a decrease in appetite.
Mental disorders: often - depression, hallucinations.
Impaired nervous system: very often - a headache, infrequently - a violation of cerebral circulation.
Disorders from the side of the organ of vision: often - conjunctivitis.
Violations from the organ of hearing and labyrinth: often - vertigo.
Heart Disease: often - angina, infrequently - myocardial infarction.
Disturbances from the respiratory system, chest and mediastinal organs: often - rhinitis
Gastrointestinal disorders: often - bloating.
Disorders from the rut and subcutaneous tissues: often - dermatitis, infrequently - a vesiculo-bullous rash.
Disturbances from muscular, skeletal and connective tissue: often - musculoskeletal disease, neck pain, arthritis.
Disorders from the kidneys and urinary tract: often - the urge to urinate. Common disorders and reactions at the site of administration: often - fever, malaise.
When used as an auxiliary therapy:
Benign, malignant and unspecified neoplasms (including cysts and polyps): infrequently - skin melanoma.
Metabolic and nutritional disorders: often - a decrease in appetite.
Mental disorders: often - hallucinations, nightmarish dreams, infrequently - confusion.
Impaired nervous system: very often - dyskinesia, often - dystonia, carpal tunnel syndrome, imbalance, infrequently - impaired cerebral circulation.
Heart Disease: infrequently - angina.
Vascular disorders: often - orthostatic hypotension.
Gastrointestinal disorders: often - abdominal pain, constipation, nausea and vomiting, dry mouth.
Disturbances from the skin and subcutaneous tissues: often - a rash.
Disturbances from muscular, skeletal and connective tissue: often - arthralgia, pain in the neck.
Common disorders and reactions at the site of administration: often - weight loss.
Injuries, intoxications and complications of procedures: often - falls.
With Parkinson's disease, hallucinations and confusion arise.According to the post-experience experience, these symptoms were noted in patients with Parkinson's disease who received rasagiline.
Serious adverse reactions that occur with the simultaneous use of SSRIs, SSRIs, tricyclic / tetracyclic antidepressants and MAO inhibitors are well known. In the post-marketing period, cases of development of serotonin syndrome, manifested in agitation, confusion, rigidity, fever and myoclonus, in patients taking antidepressants / SSRIs and rasagiline.
There is evidence of clinical trials of rasagiline, in which simultaneous use with fluoxetine or fluvoxamine was not allowed. However, the following antidepressants were allowed in these doses: amitriptyline no more than 50 mg / day, trazodone not more than 100 mg / day, citalopram not more than 20 mg / day, sertraline not more than 100 mg / day and paroxetine not more than 30 mg / day. In a clinical research program in which rasagiline was simultaneously used with tricyclic antidepressants (115 patients) and SSRIs / SSRIs (141 patients), cases of serotonin syndrome were not observed.
When rasagiline was used during the postgistribution period, it was reported that blood pressure (BP) increased, including rare cases of hypertensive crises, in patients using an undefined number of products rich in tyramine in the diet.
There are cases of drug interaction with the simultaneous use of MAO inhibitors with sympathomimetic drugs.
In the post-marketing period, a case of increased blood pressure was reported in a patient who used an ophthalmic vasoconstrictor tetrahydrozoline and simultaneously received rasagiline treatment.
Impulsive personality disorder
There have been reports of increased libido, hypersexuality, gambling, compulsive need to buy and purchase, overeating and compulsive overeating in patients treated with dopamine receptor agonists and / or other dopaminomimetics. A similar picture of impulsive personality disorder was observed in the post-marketing period in patients taking rasagiline, which was characterized by compulsive and impulsive behavior, obsessive ideas.
It is important to report suspected adverse reactions with a view to ensuring continuous monitoring of the relationship between the benefits and risks of the drug. If you experience any undesirable reactions, contact your doctor, a pharmacy worker or a manufacturer. Medical workers are advised to report any suspected adverse drug reactions through national systems reporting unwanted reactions.